Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development

@article{Shulman2008UseOA,
  title={Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development},
  author={D. Shulman and G. Francis and M. Palmert and E. Eugster},
  journal={Pediatrics},
  year={2008},
  volume={121},
  pages={e975 - e983}
}
Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of… Expand
Aromatase Inhibitors to Augment Height: Continued Caution and Study Required
  • M. Geffner
  • Medicine
  • Journal of clinical research in pediatric endocrinology
  • 2009
TLDR
It is imperative that there be well-designed, long-term studies of efficacy and safety of AI use in pediatric populations, because little is known about the short- and long- term safety of AIs in children. Expand
Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor
TLDR
An alternative strategy for management of severe growth failure in a 14-year-old child who presented with advanced chronic kidney disease close to puberty is described, with successful transplant and anticipated complete correction of height deficit. Expand
Puberty and Its Disorders in the Male
TLDR
Regulation and disorders of pubertal timing are a major focus with detailed information provided regarding the etiology, evaluation, and treatment of precocious and delayed puberty in the male. Expand
Aromatase inhibitors for short stature in male children and adolescents.
BACKGROUND As a result of the essential role of oestrogens in epiphyseal closure, aromatase inhibitors have been trialled as an intervention to improve height outcomes in male children andExpand
Aromatase inhibitor–induced hair loss in two adolescents
TLDR
Two adolescents, 14 and 16 years of age, who developed androgenetic alopecia following treatment with anastrozole for idiopathic short stature should be considered in the pediatric population undergoing treatment with aromatase inhibitors. Expand
Aromatase inhibitors in pediatrics
TLDR
Although aromatase inhibitors appear effective in increasing adult height of boys with short stature and/or pubertal delay, safety concerns, including vertebral deformities, a decrease in serum HDL cholesterol levels and increase of erythrocytosis, are reasons for caution. Expand
Growth Hormone With Aromatase Inhibitor May Improve Height in CYP11B1 Congenital Adrenal Hyperplasia
TLDR
This patient is only the second reported case of the use of an aromatase inhibitor in combination with growth hormone to optimize height in 11β-hydroxylase-deficient CAH, and this novel treatment proved to be highly efficacious, with no adverse effects. Expand
Treatment and Outcome of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency
TLDR
This special issue of the International Journal of Pediatric Endocrinology is intended to review the state of the art in medical treatment and psychological management as well as evaluations of the outcomes of patients with CAH. Expand
Cognitive effects of aromatase inhibitor therapy in peripubertal boys.
TLDR
The results suggest that blockade of oestrogen biosynthesis with an aromatase inhibitor does not influence cognitive performance in peripubertal males. Expand
Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome
TLDR
Fulvestrant was well tolerated and moderately effective in decreasing vaginal bleeding and rates of skeletal maturation in girls with MAS and long-term studies aimed at further defining potential benefits and risks of this novel therapeutic approach are needed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Use of aromatase inhibitors in children with short stature.
TLDR
A review of the studies in the pediatric population and some of the metabolic effects in adults shows a beneficial effect on bone age advancement and predicted adult height in children. Expand
Use of aromatase inhibitors to increase final height
  • L. Dunkel
  • Medicine
  • Molecular and Cellular Endocrinology
  • 2006
TLDR
Results of a randomized placebo-controlled trial in boys with delayed puberty treated withLetrozole, a selective nonsteroidal AI, found that boys treated with letrozoles + testosterone experienced delayed bone maturation and good growth response and achieved an increase in predicted adult height. Expand
Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.
TLDR
Letrozole may be effective therapy in some girls with McCune-Albright syndrome and/or gonadotropin-independent precocious puberty and possible adverse effects include ovarian enlargement and cyst formation. Expand
Testotoxicosis: current viewpoint.
TLDR
A phase II study in testotoxicosis is currently underway, exploring the combination of a highly selective anti-androgen, bicalutamide, and the potent aromatase inhibitor, anastrozole, in adult patients. Expand
Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies.
TLDR
Clomiphene citrate in a dose of 50 mg/day resulted in only small decreases in persistent pubertal gynecomastia and was not a satisfactory medical therapy for the condition. Expand
Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
TLDR
It is concluded that fadrozole is not sufficiently potent to block estrogen synthesis in most girls with gonadotropin-independent precocious puberty due to the McCune-Albright syndrome and may impair the adrenocortical stress response. Expand
Treatment of Pubertal Gynecomastia with the Specific Aromatase Inhibitor Anastrozole
TLDR
Anastrozole seems to be of benefit for the treatment of tenderness in gynecomastia and for patients in whom surgery is particularly risky, however, further double-blinded, placebo-controlled trials are necessary before a definite conclusion can be drawn about the effectiveness and the side effects of this therapy. Expand
Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial.
TLDR
Treatment with the aromatase inhibitor Lz delays bone maturation and improves PAH in boys with idiopathic short stature and no adverse effects on bone mineralization were evident after 2 yr of treatment. Expand
A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial
TLDR
The findings suggest that if oestrogen action is inhibited in growing adolescents, adult height will increase, and provides a rationale for studies that aim to delay bone maturation in several growth disorders. Expand
Gynecomastia in adolescent boys.
TLDR
It is recommended that adolescent gynecomastia should not be treated either surgically or with hormones, but that the boy and his parents should be assured that this is a normal phenomenon of puberty which will disappear within 1 or 2 years. Expand
...
1
2
3
4
5
...